Moderna Flu Vaccine: 9-0 AdComm Vote, Aug 5 PDUFA

At $57.02, Moderna has shed 16% over the past two months heading into its August 5 PDUFA for mFLUSIVA (mRNA-1010). The VRBPAC voted 9-0 that the benefits outweigh the risks on June 18. Approval is near-certain. The stock thesis is not.

Moderna needs mRNA-1010 to prove its platform works beyond COVID. The Phase 3 P304 trial showed a 26.6% relative vaccine efficacy against standard-dose flu shots in adults 50 and older. That is real. But the $22.6 billion market cap against $389 million in Q1 revenue and $1.34 billion in quarterly net losses tells you the market is pricing in far more than one flu vaccine. I think the approval pop, if it comes, gets sold.

The Trial: Good Data, Not Great Data

The Phase 3 P304 trial enrolled 40,703 participants across 11 countries during the 2024-25 flu season (ClinicalTrials.gov NCT06602024). The primary result: 2.0% of mRNA-1010 recipients developed RT-PCR-confirmed influenza-like illness versus 2.8% in the standard-dose comparator group. That works out to a relative vaccine efficacy of 26.6% (95% CI, 16.7% to 35.4%).

When measured against harder endpoints like emergency department visits, hospitalizations, and urgent care, the relative efficacy improved to 47.9%. That is the number Moderna wants investors to focus on. But the primary endpoint is about preventing confirmed flu cases, and a 26.6% improvement over standard-dose vaccines is modest in absolute terms. For context, the global flu vaccine market is estimated at $9.5 billion in 2026 (Grand View Research), growing at 6.5% annually to $14.8 billion by 2033. North America accounts for 52.7% of that revenue.

The 9-0 VRBPAC vote was unanimous but came with caveats. Panelists flagged single-season data, limited confirmed cases against influenza B/Victoria, and a compressed follow-up window. The trial was designed for 836 cases but accrued 968 cases faster than expected due to a severe 2024-25 flu season. That speed reduced the observation period. As BioPharma Dive reported, Moderna lacked data in immunocompromised and very frail older adults, and did not definitively establish efficacy against influenza B.

The safety profile is consistent with mRNA vaccines but notably worse than standard flu shots. Injection-site pain hit 65.8% of mRNA-1010 recipients versus 29.8% in the comparator group. Fatigue: 45.1% versus 20.3%. Myalgia: 35.4% versus 11.6%. These are not dealbreakers for approval, but they matter for uptake. Public skepticism around mRNA technology post-COVID is real, and higher reactogenicity gives hesitant patients another reason to skip the shot.

The Approval Pathway: Standard for 50-64, Accelerated for 65+

Moderna is seeking standard approval for ages 50-64 and accelerated approval for 65+. The accelerated pathway for the older population requires a postmarketing confirmatory trial. That matters because the 65+ segment is where flu vaccines generate the most revenue and clinical impact.

Immunogenicity data from a separate Phase 3 study in adults 65 and older showed superior antibody responses at Day 29 and six months compared to Fluzone High-Dose. That is the basis for the accelerated approval pathway. But immunogenicity is a surrogate endpoint. The P304 efficacy trial did not clearly demonstrate superiority in frail elderly patients, the subgroup where flu causes the most severe outcomes.

The FDA initially refused to review the BLA before reversing course. That reversal itself made headlines. The 9-0 AdComm vote suggests the FDA has internally aligned around approval. I rate the probability of approval by August 5 at 90% or better.

The Commercial Question: $9.5 Billion Market, Entrenched Players

This is where the investment thesis gets complicated. The global flu vaccine market is $9.5 billion in 2026. North America accounts for roughly $5 billion of that. Sanofi (SNY, $103.8 billion market cap, $43.36 close), GSK ($101.6 billion, $50.74 close), and CSL Seqirus dominate the market. These are entrenched players with decades of manufacturing infrastructure, physician relationships, and distribution contracts that Moderna cannot replicate overnight.

Sanofi alone controls roughly 40% of the global flu vaccine market through its Fluzone franchise, which includes standard-dose, high-dose, and recombinant options. GSK’s Fluarix and Flulaval lines hold another significant share. CSL Seqirus dominates the adjuvanted vaccine segment. These companies produce 150 million to 200 million flu vaccine doses annually for the US market alone. Moderna’s manufacturing capacity, built for COVID, can scale to mRNA-1010, but commercial vaccine distribution is a different game from pandemic-era government contracts.

Moderna’s pitch is that mRNA technology offers faster manufacturing and better strain matching. No egg-based culturing means no adaptation mutations that can reduce vaccine effectiveness. That is a genuine advantage. But mRNA-1010’s 26.6% rVE advantage is measured against standard-dose vaccines, which are the cheapest, least effective option on the market. The real competition for the 65+ segment is enhanced vaccines like Fluzone High-Dose and recombinant Flublok, which already outperform standard-dose shots. Moderna’s immunogenicity data suggests superiority over Fluzone High-Dose on antibody titers, but without efficacy data against enhanced vaccines in a head-to-head trial, the commercial case is incomplete.

BioNTech (BNTX, $23.3 billion market cap) is Moderna’s closest mRNA platform comp. Both are post-COVID companies trying to prove their platforms extend beyond a single vaccine. BioNTech has bet more heavily on oncology with mRNA cancer vaccine candidates in Phase 2/3. Moderna’s mRNA cancer vaccine program remains its long-term optionality, but flu is the near-term revenue driver.

At $22.6 billion, Moderna trades at roughly 58x its $389 million annualized Q1 revenue run rate. That multiple assumes massive growth from both COVID (which is declining) and new product launches. The company lost $1.34 billion in Q1 2026 alone. At that burn rate, Moderna needs to demonstrate a credible path to profitability before the market rewards the platform story.

The Stock: Down 16% and Drifting Lower

Polygon historical data shows MRNA declining from $68.27 to $57.02 over the last 10 trading sessions I pulled. The stock has been drifting lower as the PDUFA approaches, a pattern that suggests the market has already priced in approval and is uncertain about commercial uptake. The 7-week trading range spans $57.02 to $68.28, with the stock now sitting at the bottom of that range.

Finnhub news flow confirms the narrative. An earnings preview from Yahoo notes analysts expect losses to narrow, and Moderna appointed a new board member with financial expertise. These are not the headlines of a company hitting on all cylinders. Q2 earnings are due July 31, six days before the PDUFA. If the loss is wider than expected, the stock could test $52 before the FDA decision. The VRBPAC vote was 9-0, but the stock has not moved up on that news. Markets are forward-looking, and the market has already looked past the approval to the commercial reality.

Verdict

Approval on August 5 is likely. I rate it 90% probability. But I do not think the stock works from $57. The flu vaccine market is competitive and dominated by players with 10x Moderna’s revenue base. The efficacy advantage is modest against standard-dose comparators, and the reactogenicity profile could limit uptake. Moderna needs to demonstrate efficacy against enhanced vaccines like Fluzone High-Dose, not just standard-dose shots, to justify the bull case.

At $22.6 billion with $1.34 billion in quarterly losses, Moderna is a platform bet, not a flu vaccine bet. The real question is whether mRNA can compete on cost and convenience in prevention markets where Gilead’s lenacapavir for HIV PrEP is already redefining the standard of care with twice-yearly dosing.

My target: $48 to $52 by year-end. The approval pop gets faded. Moderna needs to show it can sell flu vaccines at scale before the stock re-rates. The platform story is intact but the near-term financials do not support a $22 billion valuation. I would not buy here.